君实生物（01877）今日盘中大涨5.16%，截至发稿，报价14.46港元。该股价的强劲表现主要受到公司重要产品在海外市场获批的利好消息推动。
据公司公告，君实生物的重磅产品特瑞普利单抗（新加坡商品名：LOQTORZI）近日获得新加坡卫生科学局（HSA）批准上市。该药物联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗。值得注意的是，特瑞普利单抗成为新加坡首个且唯一获批用于鼻咽癌的肿瘤免疫治疗药物，这无疑将增强公司在国际市场的竞争力。
此外，市场消息显示，君实生物还参与设立了一家生物医药并购私募基金。该基金总规模达46.6亿元，经营范围包括股权投资、投资管理、资产管理等。这一举措可能进一步拓展公司的业务布局，为未来发展提供新的增长点。投资者对公司在产品研发和市场拓展方面的积极举措反应热烈，推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.